Current in-house programmes are focussed on auto-immune, anti-inflammatory and anti-angiogenesis conditions where current first-line small molecule and biologic therapies are failing to deliver the required disease outcomes for all patients.
Using the inherent qualities of their small size, stable nature and unique neutralisation potencies, Elasmogen is developing site-specific soloMERs that can deliver rapid alleviation of disease, minimise systemic exposure and side-effects and offer the promise of self-administered, longer-term treatments.
ELN/21 and ELN/22 programs
Uveitis ranks fifth in the causes of blindness in the developed world, and is believed to be responsible for 10% of cases of visual loss in the age group of 20–60 years. The auto-immune form of this disease is characterised by a rapid and debilitating inflammation of the uvea. This is a condition that requires immediate treatment to prevent partial or total and irreversible loss of sight. The current first-line therapies are corticosteroids, but at least one third of patients fail to respond to this form of “sledge-hammer” immunomodulation with many more suffering side-effects to the steroids themselves (glaucoma and cataracts).
ELN/21 and 22 show the potential to be potent and sight-saving medicines for the treatment of this corticosteroid-refractive, patient population. Recognising validated targets, topical or site-specific delivery of soloMERs will provide immediate therapy at the point of need, limit systemic exposure and have the potential to become a patient-administered, longer term therapy for this debilitating condition.
Elasmogen has related site-specific, soloMER programmes looking to improve patient outcomes in Dry Eye, Corneal Graft Rejection and in sub-sets of patients suffering from Irritable Bowel and Crohn’s Disease.
Primary indication; Diabetic Retinopathies
Secondary indication; Age-related Macular Degeneration (AMD)
In ophthalmology, despite the dominance of anti-VEGF biologics in AMD and ischaemic retinopathies, there remains an urgent need for VEGF independent, anti-angiogenic therapies. ELN/12 provides such an alternative bringing a much needed option for for non-responding (anti-VEGF) patients (30%), or for those that develop a refractory response or significant side-effects (20%).
Elasmogen has isolated a number of ELN/21 clones based on their abilities to both block angiogenesis signalling and trigger rapid internalisation into developing vascular cells (efficiently delivering drug-warhead). It is hoped that this dual function will enhance their targeting, uptake and potency in an anti-VEGF independent manner.
ELN/41 (Proxison™) is a mito-active, mito-targeting small-molecule, super-anti-oxidant. Elasmogen is actively seeking collaborators/partners for this molecule. To discuss opportunities further please contact: firstname.lastname@example.org